Furthermore, the overexpression of IGF2BP3 in BLCA was attributed to the amplification/gain of IGF2BP3 copy number, the hypomethylation of its promoter, and the deficiency of miR-320a-3p. The gene discussed is IGF2BP3; the disease is bladder transitional cell carcinoma.